Drug intelligence / Profile preview

NBG-017

Development stage: Preclinical
Lead developer: NB Health Laboratory
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NBG-017 is a monoclonal antibody drug candidate developed by NB Health Laboratory. It acts as a modulator of G-protein coupled receptors (GPCRs), targeting these receptors to influence their activity. The primary therapeutic area under investigation for this agent is endocrinology and metabolic disease, with hypoglycemia identified as the main active indication. As of the latest available information, NBG-017 remains in the discovery phase of development and has not yet entered clinical trials or received regulatory approval[2].

Beyond the preview

Go deeper on NBG-017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBG-017.

Explore the full profile